PURPOSE: To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. PATIENTS AND METHODS: This was a single-arm, phase II study. Eligible patients had recurrent glioma after prior radiotherapy with an enhancing lesion on magnetic resonance imaging. Three different histologic groups were studied: glioblastomas (GBM), pure/mixed (anaplastic) oligodendrogliomas (OD), and low-grade or anaplastic astrocytomas (A). Imatinib was started at a dose of 600 mg/d with dose escalation to 800 mg in case of no toxicity; during the trial this dose was increased to 800 mg/d with escalation to 1,000 mg/d. Trial design was one-stage Fleming; both an objective response and 6 months of progression-free survival (PFS) were considered a successful outcome to treatment. RESULTS: A total of 112 patients (51 patients with GBM, 25 patients with A, and 36 patients with OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was 2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16% (95% CI, 8.0% to 34.0%) in GBM, 4.0% (95% CI, 0.3% to 15.0%) in OD, and 9% (95% CI, 2.0% to 25.0%) in A. The exposure to imatinib was significantly lower in patients using enzyme-inducing antiepileptic drugs. The presence of ABCG2 point mutations were not correlated with pharmacokinetic findings. No somatic activating mutations of KIT or platelet-derived growth factor receptor-A or -B were found. CONCLUSION: In the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas.
PURPOSE: To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. PATIENTS AND METHODS: This was a single-arm, phase II study. Eligible patients had recurrent glioma after prior radiotherapy with an enhancing lesion on magnetic resonance imaging. Three different histologic groups were studied: glioblastomas (GBM), pure/mixed (anaplastic) oligodendrogliomas (OD), and low-grade or anaplastic astrocytomas (A). Imatinib was started at a dose of 600 mg/d with dose escalation to 800 mg in case of no toxicity; during the trial this dose was increased to 800 mg/d with escalation to 1,000 mg/d. Trial design was one-stage Fleming; both an objective response and 6 months of progression-free survival (PFS) were considered a successful outcome to treatment. RESULTS: A total of 112 patients (51 patients with GBM, 25 patients with A, and 36 patients with OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was 2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16% (95% CI, 8.0% to 34.0%) in GBM, 4.0% (95% CI, 0.3% to 15.0%) in OD, and 9% (95% CI, 2.0% to 25.0%) in A. The exposure to imatinib was significantly lower in patients using enzyme-inducing antiepileptic drugs. The presence of ABCG2 point mutations were not correlated with pharmacokinetic findings. No somatic activating mutations of KIT or platelet-derived growth factor receptor-A or -B were found. CONCLUSION: In the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas.
Authors: HaiQing Dai; Peter Marbach; Michel Lemaire; Michael Hayes; William F Elmquist Journal: J Pharmacol Exp Ther Date: 2003-03 Impact factor: 4.030
Authors: E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Y Shoshan; A Nishiyama; A Chang; S Mörk; G H Barnett; J K Cowell; B D Trapp; S M Staugaitis Journal: Proc Natl Acad Sci U S A Date: 1999-08-31 Impact factor: 11.205
Authors: B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245
Authors: M J van den Bent; W Grisold; D Frappaz; R Stupp; J P Desir; T Lesimple; C Dittrich; M J A de Jonge; A Brandes; M Frenay; A F Carpentier; P Chollet; J Oliveira; B Baron; D Lacombe; M Schuessler; P Fumoleau Journal: Ann Oncol Date: 2003-12 Impact factor: 32.976
Authors: J Verweij; A van Oosterom; J-Y Blay; I Judson; S Rodenhuis; W van der Graaf; J Radford; A Le Cesne; P C W Hogendoorn; E D di Paola; M Brown; O S Nielsen Journal: Eur J Cancer Date: 2003-09 Impact factor: 9.162
Authors: Wolfgang Wick; Michael Weller; Markus Weiler; Tracy Batchelor; Alfred W K Yung; Michael Platten Journal: Neuro Oncol Date: 2011-06 Impact factor: 12.300
Authors: Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter Journal: Neuro Oncol Date: 2015-11 Impact factor: 12.300
Authors: B Neyns; J Sadones; C Chaskis; M Dujardin; H Everaert; S Lv; J Duerinck; O Tynninen; N Nupponen; A Michotte; J De Greve Journal: J Neurooncol Date: 2010-09-25 Impact factor: 4.130
Authors: Oliver Schnell; Valerie Albrecht; David Pfirrmann; Sabina Eigenbrod; Bjarne Krebs; Alexander Romagna; Sebastian Siller; Armin Giese; Jörg-Christian Tonn; Christian Schichor Journal: Med Oncol Date: 2018-06-07 Impact factor: 3.064
Authors: David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; Allan H Friedman; James E Herndon; Jennifer Marcello; Julie A Norfleet; Roger E McLendon; John H Sampson; Henry S Friedman Journal: J Neurooncol Date: 2009-06-28 Impact factor: 4.130
Authors: Jana Portnow; Behnam Badie; Susan Markel; An Liu; Massimo D'Apuzzo; Paul Frankel; Rahul Jandial; Timothy W Synold Journal: Eur J Cancer Date: 2013-02-04 Impact factor: 9.162
Authors: Enrico Franceschi; Roger Stupp; Martin J van den Bent; Carla van Herpen; Florence Laigle Donadey; Thierry Gorlia; Monika Hegi; Benoit Lhermitte; Lewis C Strauss; Anouk Allgeier; Denis Lacombe; Alba A Brandes Journal: Neuro Oncol Date: 2012-10-22 Impact factor: 12.300